HGH Fragment 176-191 (Frag) is a synthetic peptide corresponding to the C-terminal region of the human growth hormone sequence. It is designed to selectively replicate the hormone’s lipid metabolism pathways—specifically targeting lipolysis and the inhibition of lipogenesis—without inducing the broader anabolic effects or significant hormonal alterations associated with the full-length hormone. Evaluated primarily in animal and preliminary models, this compound demonstrates localized action on fat tissue with minimal impact on blood glucose or IGF-1 levels, and is classified strictly for research purposes.